{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:21:28Z","timestamp":1788366088649,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07481-0","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:21:35Z","timestamp":1788322895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adalimumab biosimilars compared to originator: impact on uveitic macular edema"],"prefix":"10.1007","author":[{"given":"Yael","family":"Sharon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Tomkins-Netzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael L.","family":"Niederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radgonde","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaul","family":"Sar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raz","family":"Gepstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohar","family":"Habot-Wilner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Shyriaieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamel","family":"Corredores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Rozanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Makhoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Lightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"7481_CR1","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/J.OPHTHA.2014.07.007","volume":"121","author":"O Tomkins-Netzer","year":"2014","unstructured":"Tomkins-Netzer O, Talat L, Bar A et al (2014) Long-Term Clinical Outcome and Causes of Vision Loss in Patients with Uveitis. Ophthalmology 121:2387\u20132392. https:\/\/doi.org\/10.1016\/J.OPHTHA.2014.07.007","journal-title":"Ophthalmology"},{"key":"7481_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/J.OPHTHA.2016.11.013","volume":"124","author":"RL Niederer","year":"2017","unstructured":"Niederer RL, Sharief L, Bar A et al (2017) Predictors of Long-Term Visual Outcome in Intermediate Uveitis. Ophthalmology 124:393\u2013398. https:\/\/doi.org\/10.1016\/J.OPHTHA.2016.11.013","journal-title":"Ophthalmology"},{"key":"7481_CR3","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/J.OPHTHA.2006.03.027","volume":"113","author":"CWTA Lardenoye","year":"2006","unstructured":"Lardenoye CWTA, van Kooij B, Rothova A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmology 113:1446\u20131449. https:\/\/doi.org\/10.1016\/J.OPHTHA.2006.03.027","journal-title":"Ophthalmology"},{"key":"7481_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/DDDT.S166092","volume":"13","author":"S Koronis","year":"2019","unstructured":"Koronis S, Stavrakas P, Balidis M et al (2019) Update in treatment of uveitic macular edema. Drug Des Devel Ther 13:667\u2013680. https:\/\/doi.org\/10.2147\/DDDT.S166092","journal-title":"Drug Des Devel Ther"},{"key":"7481_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/J.OPHTHA.2023.04.011","volume":"130","author":"NR Acharya","year":"2023","unstructured":"Acharya NR, Vitale AT, Sugar EA et al (2023) Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology 130:914\u2013923. https:\/\/doi.org\/10.1016\/J.OPHTHA.2023.04.011","journal-title":"Ophthalmology"},{"key":"7481_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/J.OPHTHA.2018.08.021","volume":"126","author":"JE Thorne","year":"2019","unstructured":"Thorne JE, Sugar EA, Holbrook JT et al (2019) Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 126:283\u2013295. https:\/\/doi.org\/10.1016\/J.OPHTHA.2018.08.021","journal-title":"Ophthalmology"},{"key":"7481_CR7","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1016\/j.ophtha.2015.07.036","volume":"122","author":"O Tomkins-Netzer","year":"2015","unstructured":"Tomkins-Netzer O, Lightman S, Drye L et al (2015) Outcome of Treatment of Uveitic Macular Edema: the Multicenter Uveitis Steroid Treatment Trial 2-Year Results. Ophthalmology 122:2351\u20132359. https:\/\/doi.org\/10.1016\/j.ophtha.2015.07.036","journal-title":"Ophthalmology"},{"key":"7481_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/J.OPHTHA.2022.02.002","volume":"129","author":"E Tsui","year":"2022","unstructured":"Tsui E, Rathinam SR, Gonzales JA et al (2022) Outcomes of Uveitic Macular Edema in the First-line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial. Ophthalmology 129:661\u2013667. https:\/\/doi.org\/10.1016\/J.OPHTHA.2022.02.002","journal-title":"Ophthalmology"},{"key":"7481_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/J.OPHTHA.2020.08.035","volume":"128","author":"O Tomkins-Netzer","year":"2021","unstructured":"Tomkins-Netzer O, Lightman SL, Burke AE et al (2021) Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. Ophthalmology 128:719\u2013728. https:\/\/doi.org\/10.1016\/J.OPHTHA.2020.08.035","journal-title":"Ophthalmology"},{"key":"7481_CR10","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMOA1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP et al (2016) Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 375:932\u2013943. https:\/\/doi.org\/10.1056\/NEJMOA1509852","journal-title":"N Engl J Med"},{"key":"7481_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/09273948.2022.2075761","volume":"31","author":"A Bograd","year":"2023","unstructured":"Bograd A, Fuchs D, B\u00e4chtiger J et al (2023) Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study. Ocul Immunol Inflamm 31:981\u2013988. https:\/\/doi.org\/10.1080\/09273948.2022.2075761","journal-title":"Ocul Immunol Inflamm"},{"key":"7481_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/09273948.2018.1498110","volume":"26","author":"R Lejoyeux","year":"2018","unstructured":"Lejoyeux R, Diwo E, Vallet H et al (2018) INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema. Ocul Immunol Inflamm 26:991\u2013996. https:\/\/doi.org\/10.1080\/09273948.2018.1498110;PAGE:STRING:ARTICLE\/CHAPTER","journal-title":"Ocul Immunol Inflamm"},{"key":"7481_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388:1183\u20131192. https:\/\/doi.org\/10.1016\/S0140-6736(16)31339-3","journal-title":"Lancet"},{"key":"7481_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/09273948.2018.1529466","volume":"26","author":"ET Cunningham","year":"2018","unstructured":"Cunningham ET, Zierhut M (2018) Uveitic Macular Edema. Ocul Immunol Inflamm 26:987\u2013990. https:\/\/doi.org\/10.1080\/09273948.2018.1529466","journal-title":"Ocul Immunol Inflamm"},{"key":"7481_CR15","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.2147\/DDDT.S160431","volume":"12","author":"S Ming","year":"2018","unstructured":"Ming S, Xie K, He H et al (2018) Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: A meta-analysis and systematic review. Drug Des Devel Ther 12:2005\u20132016. https:\/\/doi.org\/10.2147\/DDDT.S160431","journal-title":"Drug Des Devel Ther"},{"key":"7481_CR16","doi-asserted-by":"publisher","first-page":"591134","DOI":"10.3389\/FPHAR.2020.591134\/BIBTEX","volume":"11","author":"E Moorkens","year":"2021","unstructured":"Moorkens E, Godman B, Huys I et al (2021) The Expiry of Humira\u00ae Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Front Pharmacol 11:591134. https:\/\/doi.org\/10.3389\/FPHAR.2020.591134\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"7481_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/J.PHRS.2018.01.024","volume":"133","author":"R G\u00e1mez-Belmonte","year":"2018","unstructured":"G\u00e1mez-Belmonte R, Hern\u00e1ndez-Chirlaque C, Arredondo-Amador M et al (2018) Biosimilars: Concepts and controversies. Pharmacol Res 133:251\u2013264. https:\/\/doi.org\/10.1016\/J.PHRS.2018.01.024","journal-title":"Pharmacol Res"},{"key":"7481_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/09273948.2023.2172591","volume":"32","author":"GM Murray","year":"2024","unstructured":"Murray GM, Griffith N, Sinnappurajar P et al (2024) Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis. Ocul Immunol Inflamm 32:442\u2013446. https:\/\/doi.org\/10.1080\/09273948.2023.2172591","journal-title":"Ocul Immunol Inflamm"},{"key":"7481_CR19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/S40123-021-00387-6","volume":"10","author":"J Sota","year":"2021","unstructured":"Sota J, Gentileschi S, Perfetti MO et al (2021) Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Beh\u00e7et\u2019s Syndrome. Ophthalmol Ther 10:1129\u20131135. https:\/\/doi.org\/10.1007\/S40123-021-00387-6","journal-title":"Ophthalmol Ther"},{"key":"7481_CR20","doi-asserted-by":"publisher","unstructured":"Song SH, Woo SJ (2024) Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis. Ocul Immunol Inflamm 32. https:\/\/doi.org\/10.1080\/09273948.2023.2295544","DOI":"10.1080\/09273948.2023.2295544"},{"key":"7481_CR21","doi-asserted-by":"publisher","first-page":"486841","DOI":"10.3389\/FPHAR.2019.01468\/BIBTEX","volume":"10","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Vitale A, Emmi G et al (2019) The role of biosimilars in uveitis: Long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors. Front Pharmacol 10:486841. https:\/\/doi.org\/10.3389\/FPHAR.2019.01468\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"7481_CR22","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/09273948.2021.1900276","volume":"30","author":"M Soheilian","year":"2022","unstructured":"Soheilian M, Ebrahimiadib N, Hedayatfar A et al (2022) Efficacy of Biosimilar Adalimumab in the Treatment of Beh\u00e7et\u2019s Uveitis. Ocul Immunol Inflamm 30:1495\u20131500. https:\/\/doi.org\/10.1080\/09273948.2021.1900276","journal-title":"Ocul Immunol Inflamm"},{"key":"7481_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/APO.0000000000000380","volume":"10","author":"J Sota","year":"2021","unstructured":"Sota J, Gentileschi S, Vitale A et al (2021) Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience. Asia Pac J Ophthalmol (Phila) 10:360\u2013365. https:\/\/doi.org\/10.1097\/APO.0000000000000380","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"7481_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/S40123-023-00863-1","volume":"13","author":"M Tarsia","year":"2024","unstructured":"Tarsia M, Vitale A, Gaggiano C et al (2024) Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry. Ophthalmol Ther 13:761\u2013774. https:\/\/doi.org\/10.1007\/S40123-023-00863-1","journal-title":"Ophthalmol Ther"},{"key":"7481_CR25","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14712598.2022.2123703","volume":"23","author":"K Ulu","year":"2023","unstructured":"Ulu K, \u00c7akan M, \u00c7a\u011flayan \u015e et al (2023) Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases. Expert Opin Biol Ther 23:833\u2013839. https:\/\/doi.org\/10.1080\/14712598.2022.2123703","journal-title":"Expert Opin Biol Ther"},{"key":"7481_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/BJO-2025-327767","author":"O Tomkins-Netzer","year":"2025","unstructured":"Tomkins-Netzer O, Niederer RL, Amer R et al (2025) Adalimumab biosimilars have similar efficacy to originator adalimumab when treating non-infectious uveitis. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/BJO-2025-327767. bjo-2025-327767","journal-title":"Br J Ophthalmol"},{"key":"7481_CR27","doi-asserted-by":"crossref","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509\u201316","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"7481_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/JOP.2007.0104","volume":"24","author":"M Diaz-Llopis","year":"2008","unstructured":"Diaz-Llopis M, Garc\u00eda-Delpech S, Salom D et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24:351\u2013361. https:\/\/doi.org\/10.1089\/JOP.2007.0104","journal-title":"J Ocul Pharmacol Ther"},{"key":"7481_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/BJOPHTHALMOL-2011-301401","volume":"97","author":"BC Dobner","year":"2013","unstructured":"Dobner BC, Max R, Becker MD et al (2013) A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol 97:134\u2013138. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2011-301401","journal-title":"Br J Ophthalmol"},{"key":"7481_CR30","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/J.OPHTHA.2012.02.018","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","unstructured":"D\u00edaz-Llopis M, Salom D, Garcia-De-Vicu\u00f1a C et al (2012) Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients. Ophthalmology 119:1575\u20131581. https:\/\/doi.org\/10.1016\/J.OPHTHA.2012.02.018","journal-title":"Ophthalmology"},{"key":"7481_CR31","doi-asserted-by":"publisher","unstructured":"Abitbol V, Benkhalifa S, Habauzit C, Marotte H (2023) Navigating adalimumab biosimilars: an expert opinion. J Comp Eff Res 12. https:\/\/doi.org\/10.57264\/CER-2023-0117\/ASSET\/71C570F0-E5C8-40E0-866D-97F0A1298800\/ASSETS\/IMAGES\/LARGE\/FIGURE1.JPG","DOI":"10.57264\/CER-2023-0117\/ASSET\/71C570F0-E5C8-40E0-866D-97F0A1298800\/ASSETS\/IMAGES\/LARGE\/FIGURE1.JPG"},{"key":"7481_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09273948.2019.1576910","volume":"27","author":"M Accorinti","year":"2019","unstructured":"Accorinti M, Okada AA, Smith JR, Gilardi M (2019) Epidemiology of Macular Edema in Uveitis. Ocul Immunol Inflamm 27:169\u2013180. https:\/\/doi.org\/10.1080\/09273948.2019.1576910","journal-title":"Ocul Immunol Inflamm"},{"key":"7481_CR33","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/OPTH.S180580","volume":"13","author":"H Massa","year":"2019","unstructured":"Massa H, Pipis SY, Adewoyin T et al (2019) Macular edema associated with non-infectious uveitis: Pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol 13:1761\u20131777. https:\/\/doi.org\/10.2147\/OPTH.S180580","journal-title":"Clin Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07481-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:03:47Z","timestamp":1788365027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07481-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":33,"alternative-id":["7481"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07481-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. Prof. Michal Kramer is a consultant for BioNanoSim.","order":1,"name":"Ethics","label":"Disclosure of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}